3NQ Stock Overview
Researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NANO MRNA Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥0.95 |
| 52 Week High | JP¥1.50 |
| 52 Week Low | JP¥0.69 |
| Beta | 0.31 |
| 11 Month Change | 8.52% |
| 3 Month Change | -21.72% |
| 1 Year Change | -31.79% |
| 33 Year Change | -56.19% |
| 5 Year Change | -66.37% |
| Change since IPO | -96.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3NQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 7.9% | -0.2% | 0.8% |
| 1Y | -31.8% | -16.9% | 9.1% |
Return vs Industry: 3NQ underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 3NQ underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 3NQ volatility | |
|---|---|
| 3NQ Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3NQ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 3NQ's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 18 | Shiro Akinaga | www.nanomrna.co.jp |
NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer.
NANO MRNA Co.,Ltd. Fundamentals Summary
| 3NQ fundamental statistics | |
|---|---|
| Market cap | €74.64m |
| Earnings (TTM) | -€5.07m |
| Revenue (TTM) | €315.24k |
236.8x
P/S Ratio-14.7x
P/E RatioIs 3NQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3NQ income statement (TTM) | |
|---|---|
| Revenue | JP¥51.00m |
| Cost of Revenue | JP¥9.00m |
| Gross Profit | JP¥42.00m |
| Other Expenses | JP¥863.00m |
| Earnings | -JP¥821.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -11.63 |
| Gross Margin | 82.35% |
| Net Profit Margin | -1,609.80% |
| Debt/Equity Ratio | 36.2% |
How did 3NQ perform over the long term?
See historical performance and comparison